- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05458401
EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan (EUROPA T-DXd)
EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan Through a Named Patient Program (EUROPA T-DXd)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The antibody-drug conjugate T-DXd has been granted conditional approval in the European Union as a single agent for adult patients with unresectable or metastatic HER2+ breast cancer who have previously received ≥2 HER2-based regimens. This was based on data from the Phase II DESTINY-Breast01 trial (NCT03248492).
DS8201-0002-EAP-MA is a real world data (RWD) observational data collection inviting patients with advanced/metastatic HER2+ breast cancer receiving T-DXd through the NPP already to participate to help further understand the usage in a real world clinical setting.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Contact for Clinical Trial Information
- Phone Number: 908-992-6400
- Email: CTRinfo@dsi.com
Study Locations
-
-
-
Dublin, Ireland, D04 T6F4
- St. Vincent's University Hospital
-
Dublin, Ireland, D04 N2EO
- St. Vincent's Private Hospital
-
-
-
-
-
Naples, Italy, 80131
- National Cancer Instutute 'Fondazione Pascale
-
Padua, Italy, 35128
- Institute Oncology Veneto
-
Rome, Italy, 00128
- Università Campus Bio-Medico di Roma
-
Rome, Italy, 00161
- Policlinico Umberto I Di Roma
-
Rome, Italy, 00168
- Fondazione Policlinico Univeritario Agostino Gemeli
-
-
Milano
-
Rozzano, Milano, Italy, 20089
- Breast Center Humanitas Cancer Center IRCCS Istituto Clinico Humanitas
-
-
Pordenone
-
Aviano, Pordenone, Italy, 33081
- Centro di riferimento Oncologico (CRO), National Cancer Institute
-
-
-
-
-
Alicante, Spain, 03010
- Hospital General Universitario de Alicante
-
Barcelona, Spain, 08003
- Hospital del Mar
-
Barcelona, Spain, 08036
- Hospital Clínic de Barcelona
-
Barcelona, Spain, 08035
- Hospital Val d'Hebron
-
Barcelona, Spain, 08023
- Hospital Quiron Salud Barcelona
-
Gerona, Spain, 17007
- ICO Girona
-
Jaén, Spain, 23007
- Hospital Universitario de Jaén
-
Madrid, Spain, 28040
- Hospital Clínico San Carlos
-
Madrid, Spain, 28046
- Hospital Universitario La Paz
-
Madrid, Spain, 28041
- Hospital 12 de Octubre
-
Sevilla, Spain, 41013
- Hospital Universitario Virgen del Rocio
-
Valencia, Spain, 46009
- Fundacion Instituto Valenciano de Oncologia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participants for whom T-DXd treatment is indicated, according to the summary of product characteristics conditionally approved by the EMA, that are eligible for treatment with T-DXd through the NPP (i.e., those with advanced/metastatic HER2+ breast cancer who have received ≥ 2 prior anti-HER2-based regimens and have documentation of HER2 positive tumour status by a validated method) will be eligible for inclusion to this RWD collection, subject to providing written informed consent to participate.
Exclusion Criteria:
- Any participant who does not meet all inclusion criteria noted above.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Trastuzumab Deruxtecan (T-DXd) Cohort
Patients with advanced/metastatic HER2-positive breast cancer who are receiving treatment (or previously treated) with trastuzumab deruxtecan (T-DXd).
|
No drug will be administered during this study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Real-World Time-to-Treatment Discontinuation In Participants Treated With Trastuzumab Deruxtecan (T-DXd)
Time Frame: From the time from T-DXd initiation to the date of T-DXd discontinuation, up to 14 months
|
Real-world time-to-treatment discontinuation (rwTTD) is defined as the time from trastuzumab deruxtecan initiation to discontinuation for any reason in patients with advanced/metastatic HER2+ breast cancer in a real-world clinical setting.
|
From the time from T-DXd initiation to the date of T-DXd discontinuation, up to 14 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Type of Prior Targeted HER2-targeted Treatments In Participants Treated With Trastuzumab Deruxtecan (T-DXd)
Time Frame: Prior to time of T-DXd initiation
|
Prior to time of T-DXd initiation
|
|
Number of Participants Who Discontinued Trastuzumab Deruxtecan (T-DXd) In Participants Treated With T-DXd
Time Frame: From the time from T-DXd initiation to the date of T-DXd discontinuation, up to 14 months
|
From the time from T-DXd initiation to the date of T-DXd discontinuation, up to 14 months
|
|
Number of Participants With Treatment-emergent Adverse Events In Participants Treated With Trastuzumab Deruxtecan (T-DXd)
Time Frame: From the time from T-DXd initiation to the date of T-DXd discontinuation, up to 14 months
|
From the time from T-DXd initiation to the date of T-DXd discontinuation, up to 14 months
|
|
Number of Participants Who Received Prophylaxis Treatment In Participants Treated With Trastuzumab Deruxtecan (T-DXd)
Time Frame: Prior to time of T-DXd initiation
|
Patients who received prophylaxis treatment for nausea and/or vomiting will be reported.
|
Prior to time of T-DXd initiation
|
Real World Progression-free Survival In Participants Treated With Trastuzumab Deruxtecan (T-DXd)
Time Frame: From the time of T-DXd initiation to the date of T-DXd discontinuation, withdrawal, or disease progression, up to 14 months
|
Real world progression-free survival (rwPFS) is defined as the time from T-DXd initiation to the earliest of death or progression.
|
From the time of T-DXd initiation to the date of T-DXd discontinuation, withdrawal, or disease progression, up to 14 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Global Clinical Leader, Daiichi Sankyo
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DS8201-0002-EAP-MA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HER2-positive Breast Cancer
-
Mersana TherapeuticsRecruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Non-Small Cell Lung Cancer | HER2-positive Colorectal Cancer | HER2-positive Tumors | HER2 Low Breast CancerUnited States
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
MacroGenicsApproved for marketingHER2-positive Breast Cancer | HER2-positive Carcinoma
-
Spanish Breast Cancer Research GroupSeagen Inc.RecruitingHER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast CarcinomaSpain
-
University of ArizonaPfizerCompletedBreast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | Recurrent Breast Cancer | HER2 Positive Breast Carcinoma | Breast Cancer StageUnited States
-
Enliven TherapeuticsRecruitingColorectal Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2 Amplification | HER2 Positive Solid TumorsUnited States
-
Cancer Trials IrelandCompletedBreast Cancer | HER2 Positive Breast Cancer | HER2 Negative Breast CancerIreland
-
Ruth O'ReganUniversity of Rochester; Puma Biotechnology, Inc.RecruitingBreast Cancer | HER2-positive Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast CancerUnited States
-
Daiichi SankyoRecruitingBreast Cancer | Advanced Cancer | HER2-positive Breast Cancer | HER2-low Breast CancerChina
-
Clovis Oncology, Inc.TerminatedBreast Cancer | Metastatic Breast Cancer | Estrogen Receptor Positive | Triple Negative | HER2 | HER2 Positive | MBC | ERUnited States
Clinical Trials on Trastuzumab deruxtecan
-
AstraZenecaDaiichi SankyoCompletedBreast CancerDenmark, Finland, Italy, Norway, Spain, Sweden, Poland, United States, Canada, Germany, Japan, Netherlands, Portugal, Switzerland, Australia, United Kingdom, Belgium, Ireland
-
Fudan UniversityNot yet recruitingTriple-Negative Breast CancerChina
-
Fudan UniversityActive, not recruiting
-
AstraZenecaDaiichi Sankyo Co., Ltd.Active, not recruitingGastric or Gastroesophageal Junction (GEJ) AdenocarcinomaChina
-
Daiichi Sankyo, Inc.AstraZenecaRecruiting
-
Cancer Trials IrelandRecruitingHER2-positive Breast CancerIreland
-
MedSIRDaiichi Sankyo, Inc.Not yet recruitingBreast Cancer | Metastatic Breast Cancer
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruiting
-
National Cancer Institute (NCI)SuspendedOsteosarcoma | Recurrent OsteosarcomaUnited States
-
Medical University of ViennaDaiichi Sankyo, Inc.CompletedBreast Cancer Stage IVAustria